Literature DB >> 11311056

Novel peptide conjugates for tumor-specific chemotherapy.

M Langer1, F Kratz, B Rothen-Rutishauser, H Wunderli-Allenspach, A G Beck-Sickinger.   

Abstract

One of the major problems in cancer chemotherapy are the severe side effects that limit the dose of the anticancer drugs because of their unselectivity for tumor versus normal cells. In the present work, we show that coupling of anthracyclines to peptides is a promising approach to obtain selectivity. The peptide-drug conjugate was designed to bind to specific receptors expressed on the tumor cells with subsequent internalization of the ligand-receptor complex. Neuropeptide Y (NPY), a 36-amino acid peptide of the pancreatic polypeptide family, was chosen as model peptide because NPY receptors are overexpressed in a number of neuroblastoma tumors and the thereof derived cell lines. Daunorubicin and doxorubicin, two widely used antineoplastic agents in tumor therapy, were covalently linked to NPY via two spacers that differ in stability: an acid-sensitive hydrazone bond at the 13-keto position of daunorubicin and a stable amide bond at the 3'-amino position of daunorubicin and doxorubicin. Receptor binding of these three conjugates ([C(15)]-NPY-Dauno-HYD, [C(15)]-NPY-Dauno-MBS, and [C(15)]-NPY-Doxo-MBS) was determined at the human neuroblastoma cell line SK-N-MC, which selectively expresses the NPY Y(1) receptor subtype, and cytotoxic activity was evaluated using a XTT-based colorimetric cellular cytotoxicity assay. The different conjugates were able to bind to the receptor with affinities ranging from 25 to 51 nM, but only the compound containing the acid-sensitive bond ([C(15)]-NPY-Dauno-HYD) showed cytotoxic activity comparable to the free daunorubicin. This cytotoxicity is Y(1) receptor-mediated as shown in blocking studies with BIBP 3226, because tumor cells that do not express NPY receptors were sensitive to free daunorubicin, but not to the peptide-drug conjugate. The intracellular distribution was investigated by confocal laser scanning microscopy. We found evidence that the active conjugate [C(15)]-NPY-Dauno-HYD releases daunorubicin, which is localized close to the nucleus, whereas the inactive conjugate [C(15)]-NPY-Dauno-MBS is distributed distantly from the nucleus and does not seem to release the drug within the cell.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311056     DOI: 10.1021/jm001065f

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant--taxoid conjugates as novel cytotoxic agents.

Authors:  Kyoko Nakagawa-Goto; Koji Yamada; Seikou Nakamura; Tzu-Hsuan Chen; Po-Cheng Chiang; Kenneth F Bastow; Shao-Chun Wang; Bill Spohn; Mien-Chie Hung; Fang-Yu Lee; Fang-Chen Lee; Kuo-Hsiung Lee
Journal:  Bioorg Med Chem Lett       Date:  2007-07-04       Impact factor: 2.823

Review 2.  Antimicrobial peptides with cell-penetrating peptide properties and vice versa.

Authors:  Katrin Splith; Ines Neundorf
Journal:  Eur Biophys J       Date:  2011-02-19       Impact factor: 1.733

3.  Photocaged permeability: a new strategy for controlled drug release.

Authors:  M Michael Dcona; Deboleena Mitra; Rachel W Goehe; David A Gewirtz; Deborah A Lebman; Matthew C T Hartman
Journal:  Chem Commun (Camb)       Date:  2012-04-04       Impact factor: 6.222

4.  Catalytic synthesis of amino acid and peptide derivatized gadonanotubes.

Authors:  Yuri Mackeyev; Keith B Hartman; Jeyarama S Ananta; Adrian V Lee; Lon J Wilson
Journal:  J Am Chem Soc       Date:  2009-06-24       Impact factor: 15.419

5.  Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice.

Authors:  Li-Chun Sun; L Vienna Mackey; Jing Luo; Joseph A Fuselier; David H Coy
Journal:  Clin Med Oncol       Date:  2008-08-19

6.  Triostin A derived hybrid for simultaneous DNA binding and metal coordination.

Authors:  Eike-F Sachs; André Nadler; Ulf Diederichsen
Journal:  Amino Acids       Date:  2010-10-22       Impact factor: 3.520

7.  Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers.

Authors:  David Chatenet; Renzo Cescato; Beatrice Waser; Judit Erchegyi; Jean E Rivier; Jean Claude Reubi
Journal:  EJNMMI Res       Date:  2011-09-02       Impact factor: 3.138

8.  Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Thiouracil Derivatives as Potential Antithyroid Agents.

Authors:  Samir M Awad; Yasser M Zohny; Sahar A Ali; Shahenda Mahgoub; Ahmed M Said
Journal:  Molecules       Date:  2018-11-08       Impact factor: 4.411

9.  Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.

Authors:  Lutz F Tietze; Olaf Panknin; Birgit Krewer; Felix Major; Ingrid Schuberth
Journal:  Int J Mol Sci       Date:  2008-05-20       Impact factor: 6.208

Review 10.  Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies.

Authors:  Paul Hoppenz; Sylvia Els-Heindl; Annette G Beck-Sickinger
Journal:  Front Chem       Date:  2020-07-07       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.